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Abstract 
Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct 
comparisons with active glucose-lowering comparators in drug-naive patients have demonstrated that DPP-4 
inhibitors exert slightly less pronounced HbA1c reduction than metformin (with the advantage of better 
gastrointestinal tolerability) and similar glucose-lowering effects as with a thiazolidinedione (TZD; with the 
advantage of no weight gain). In metformin-treated patients, gliptins were associated with similar HbA1c 
reductions compared with a sulphonylurea (SU; with the advantage of no weight gain, considerably fewer 
hypoglycaemic episodes and no need for titration) and a TZD (with the advantage of no weight gain and better 
overall tolerability). DPP-4 inhibitors also exert clinically relevant glucose-lowering effects compared with a 
placebo in patients treated with SU or TZD (of potential interest when metformin is either not tolerated or 
contraindicated), and as oral triple therapy with a good tolerability profile when added to a metformin-SU or 
pioglitazone-SU combination. Several clinical trials also showed a consistent reduction in HbA1c when DPP-4 
inhibitors were added to basal insulin therapy, with no increased risk of hypoglycaemia. Because of the complex 
pathophysiology of type 2 diabetes and the complementary actions of glucose-lowering agents, initial 
combination of a DPP-4 inhibitor with either metformin or a glitazone may be applied in drug-naive patients, 
resulting in greater efficacy and similar safety compared with either drug as monotherapy. However, DPP-4 
inhibitors were less effective than GLP-1 receptor agonists for reducing HbA1c and body weight, but offer the 
advantage of being easier to use (oral instead of injected administration) and lower in cost. Only one head-to-
head trial demonstrated the non-inferiority of saxagliptin vs sitagliptin. Clearly, more trials of direct comparisons 
between different incretin-based therapies are needed. Because of their pharmacokinetic characteristics, 
pharmacodynamic properties (glucose-dependent glucose-lowering effect) and good overall tolerability profile, 
DPP-4 inhibitors may have a key role to play in patients with renal impairment and in the elderly. The role of 
DPP-4 inhibitors in the therapeutic armamentarium of type 2 diabetes is rapidly evolving as their potential 
strengths and weaknesses become better defined mainly through controlled clinical trials. 
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Résumé 
Les inhibiteurs de la DPP-4 dans le traitement du diabète de type 2 : revue critique des essais cliniques 
contrôlés. 
Les inhibiteurs de la dipeptidylpeptidase-4 (DPP-4) offrent de nouvelles options pour le traitement du diabète de 
type 2. Des comparaisons directes avec d'autres médicaments antidiabétiques chez des patients naïfs de tout 
traitement ont démontré que les inhibiteurs de la DPP-4 étaient un peu moins puissants pour diminuer le taux 
d'HbA1c que la metformine (avec l'avantage d'une meilleure tolérance digestive) et aussi puissants que les 
thiazolidinediones (avec l'avantage d'une neutralité pondérale). Chez les patients déjà traités par metformine, les 
gliptines entraînent une baisse des taux d'HbA1c similaire à celle observée avec les sulfamides (mais sans prise de 
poids, sans hypoglycémie et sans nécessité de titration) ou avec les thiazolidinediones (avec l'avantage de 
l'absence de prise de poids et d'un meilleur profil de tolérance). Les inhibiteurs de la DPP-4 améliorent aussi le 
contrôle glycémique par rapport à un placebo chez les patients traités avec un sulfamide ou une thiazolidinedione 
(ce qui peut être intéressant chez les patients pour lesquels la metformine est non tolérée ou contre-indiquée) ou 
encore en triple thérapie orale en étant ajoutés à une combinaison metformine-sulfamide ou pioglitazone-
sulfamide, avec toujours un bon profil de tolérance. Plusieurs essais cliniques ont montré une diminution 
consistante des taux d'HbA1c lorsqu'un inhibiteur de la DPP-4 était ajouté à une insulinothérapie basale, sans 
accroître le risque d'hypoglycémie. En raison de la physiopathologie complexe du diabète de type 2 et de la 
complémentarité d'action des médicaments hypoglycémiants, une combinaison initiale d' un inhibiteur de la 
DPP-4 avec soit la metformine, soit une glitazone peut être proposée chez les patients insuffisamment contrôlés 
par régime et exercice, avec une meilleure efficacité et une aussi bonne tolérance qu'une monothérapie 
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pharmacologique initiale. Les inhibiteurs de la DPP-4 sont moins efficaces que les agonistes des récepteurs du 
glucagon-like peptide-1 en ce qui concerne la diminution des taux d'HbA1c et du poids, mais offrent le bénéfice 
d'un usage plus facile (prise orale au lieu d'une injection) et d'un coût moins élevé. Un seul essai clinique 
comparatif direct a été publié à ce jour entre deux inhibiteurs de la DPP-4, démontrant une non infériorité de la 
saxagliptine par rapport à la sitagliptine. De toute évidence, davantage d'essais cliniques devraient offrir une 
comparaison directe entre les différents traitements fondés sur l'effet incrétine. En raison de leurs caractéristiques 
pharmacocinétiques, de leurs propriétés pharmacodynamiques (effet hypoglycémiant glucose-dépendant) et de 
leur bon profil de tolérance, les gliptines devraient occuper une place de choix chez les patients avec une 
insuffisance rénale ou chez les sujets âgés. Le rôle des inhibiteurs de la DPP-4 dans l'arsenal thérapeutique du 
diabète de type 2 évolue rapidement au fur et à mesure que leurs avantages et inconvénients apparaissent mieux 
définis, essentiellement grâce aux essais cliniques contrôlés. 
Mots clés : Diabète de type 2 ; Essai clinique ; Inhibiteur de la DPP-4 ; Alogliptine ; Linagliptine ; Saxagliptine ; 
Sitagliptine ; Vildagliptine ; Revue générale 
 
1.  Introduction 
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a novel pharmacological class of glucose-lowering agents that 
open up new perspectives for the management of type 2 diabetes mellitus (T2DM). The mechanism of action of 
DPP-4 inhibitors is distinct from any existing class of oral glucose-lowering agents [1]. Although they are not 
more potent in lowering blood glucose concentrations and reducing glycated haemoglobin (HbA1c) levels [2], 
DPP-4 inhibitors nevertheless offer several clinically relevant advantages [3-5]. Among the most important 
benefits are a negligible risk of hypoglycaemia that is considerably lower than that observed with sulphonylurea 
(SU), and a weight-neutral profile in contrast to the weight gain generally observed with SU and 
thiazolidinedione (TZD). DPP-4 inhibitors have been evaluated as monotherapy and in various combinations 
with other glucose-lowering agents, and compared with either a placebo or an agent of another glucose-lowering 
pharmacological class as an active comparator [6]. 
The present review is an updated evaluation of five DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, 
alogliptin and linagliptin) in randomized clinical trials in the literature so far, and focuses particularly on the 
following topics: 
•  direct comparisons with active glucose-lowering comparators in drug-naive or metformin-treated patients; 
•  comparisons with placebo or active comparators in more unusual indications as an add-on to SU or TZD, as 
oral triple therapy or as an add-on to insulin; 
•  use as the initial combination with metformin or TZD in drug-naive patients; 
•  comparisons with glucagon-like peptide-1 (GLP-1) receptor agonists or other gliptins in head-to-head trials; 
•  use of DPP-4 inhibitors in special populations, especially patients with renal impairment and the elderly. 
 
2.  Methods 
To identify the relevant studies, an extensive literature search of Medline was performed from January 2005 to 
August 2011, using the term "DPP-4 inhibitors", and the generic names "sitagliptin", "vildagliptin", 
"saxagliptin", "alogliptin" and "linagliptin". No language restrictions were imposed. Reference lists of original 
studies, narrative reviews and previous systematic reviews were also carefully examined. Only clinical trials that 
randomized at least 100 T2DM patients and lasted at least 12 weeks were considered. Most of the studies ran for 
24-26 weeks, with a maximum follow-up duration of 104 weeks in a few cases. 
 
3. Results 
3.1. Gliptins as monotherapy or as add-ons to metformin 
Numerous placebo-controlled trials have demonstrated both the efficacy and safety of DPP-4 inhibitors in 
patients with T2DM treated with diet and exercise (drug-naive patients), and in patients treated with metformin 
monotherapy, the first-line drug choice for T2DM. All of these trials showed that DPP-4 inhibitors reduced 
HbAlc, fasting plasma glucose and postprandial glucose levels without inducing hypoglycaemia, with near 
weight neutrality and a tolerability profile that did not differ from that of placebo. These trials have already been 
summarized in various reviews [7] and meta-analyses [2,8]. Clinically relevant reductions in HbAlc were 
obtained with a gliptin across a wide range of T2DM patient subgroups examined by either specific baseline 
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demographic characteristics or β-cell function indices such as the homoeostatic model assessment (HOMA)-β 
[9]. Our present report has specifically compared DPP-4 inhibitors with active glucose-lowering comparators 
(instead of a placebo) to better delineate the potential advantages (and disadvantages) of DPP-4 inhibitors in 
clinical use. 
3.1.1. Gliptins as monotherapy 
As metformin is considered the first-line drug therapy for the management of T2DM [10,11], it is of interest to 
compare the efficacy (and safety) of aDPP-4 inhibitor with that of metformin in drug-naive T2DM patients 
insufficiently controlled with diet and exercise [12-21]. Overall, metformin (1000-2000 mg/day) demonstrated 
slightly (but significantly) greater reductions in both HbA1c and body weight (Table 1, Fig. 1). However, the 
DPP-4 inhibitor showed superior gastrointestinal tolerability compared with metformin. Nevertheless, these 
comparative results do not support the initial use of a DPP-4 inhibitor instead of the reference drug metformin 
except in patients for whom metformin is either not well tolerated (gastrointestinal adverse events) or is 
contraindicated (for instance, renal insufficiency). 
Only three head-to-head trials have compared a DPP-4 inhibitor with a TZD (two with pioglitazone 30 mg and 
one with rosiglitazone 8mg) [22-24]. Overall, the reduction in HbA1c was similar with the two pharmacological 
approaches, with a low incidence of hypoglycaemic events. However, the TZDs were associated with significant 
weight gain in contrast to the weight neutrality of gliptins (Table 1, Fig. 1). 
Two studies compared a DPP-4 inhibitor with an alpha-glucosidase inhibitor as monotherapy in patients with 
T2DM. One trial compared vildagliptin 50 mg with acarbose (titrated up to 3x100mg) and reported similar 
HbA1c reductions with the two compounds [25], while the other trial demonstrated that linagliptin (5 or l0mg 
once a day) had greater efficacy than voglibose (3 × 0.2 mg/day) for improving glycaemic control [26]. In both 
these studies, drug-related gastrointestinal disorders were more common with the alpha-glucosidase inhibitor 
than with the DPP-4 inhibitor (Table 1). 
 
3.1.2. Gliptins combined with metformin 
As metformin is considered the first-line drug in T2DM, most combination trials have tested the efficacy and 
safety of adding a DPP-4 inhibitor to baseline metformin monotherapy, and found that adding any gliptin was 
superior to a placebo, with a mean reduction in HbA1c of 0.6-0.8% [7]. However, in the present review, only 
head-to-head trials vs active comparators are presented in brief. Gliptins have also been compared with SUs 
(glimepiride, glipizide, gliclazide) [27-34], TZDs (pioglitazone 30 mg, rosiglitazone 8 mg) [35-39] and GLP-1 
receptor agonists (exenatide, liraglutide) [36,40,41]. However, only one head-to-head study compared two 
different DPP-4 inhibitors in the same trial: saxagliptin 5 mg with sitaglitptin 100 mg as add-ons to basal 
metformin therapy [42]. 
Compared with SU, a DPP-4 inhibitor generally led to a similar reduction in HbA1c levels and a similar increase 
in the proportion of patients achieving HbA1c levels < 7% (53 mmol/mol; Table 2, Fig. 1), but with a much lower 
incidence of hypoglycaemic events. SU therapy was associated with modest weight gain, whereas the 
administration of a gliptin resulted in no weight change or even modest weight loss (Table 1, Fig. 1). In the two 
longest-running trials, the 'escape phenomenon', assessed by a secondary increase in HbA1c levels between weeks 
24 and 104 following a good initial HbA1c reduction, was significantly less pronounced with sitagliptin 100 mg 
or vildagliptin 100 mg than with glipizide or glimepiride, respectively [28,31], suggesting better β-cell protection 
and durability of glucose control with a DPP-4 inhibitor. 
Compared with a TZD, a DPP-4 inhibitor was not inferior as regards improvement of glucose control (Table 2, 
Fig. 1). Initial observations had suggested that DPP-4 inhibitors might be less potent than TZDs. However, when 
considering the results of different trials in indirect comparisons, it is crucial to adjust treatment-induced HbA1c 
reductions in relation to baseline values [43,44]. In this case, the differences between gliptins and TZDs that had 
initially appeared almost disappeared and, thus, were in agreement with the head-to-head comparisons analyzed 
in the present report. However, there was a clear-cut difference between the two pharmacological classes in 
terms of body-weight changes. A significant weight increase was observed in all trials with TZDs in contrast to 
the weight neutrality seen with DPP-4 inhibitors (Table 2, Fig. 1). 
3.2. Gliptins in special combinations 
3.2.1. Gliptins combined with sulphonylureas 
Several trials have evaluated the efficacy and safety of adding a DPP-4 inhibitor vs a placebo to SU monotherapy 
(glimepiride or glyburide). This may be of interest in patients who cannot be treated with metformin. Compared 
with a placebo, sitagliptin 100 mg (once daily) [45] and vildagliptin (50 or 100 mg daily) [46] significantly 
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improved glycaemic control and β-cell function, and were well tolerated in T2DM patients with inadequate 
glycaemic control with glimepiride alone. Similar results were reported in T2DM patients with the addition of 
alogliptin (12.5 mg or 25 mg) to glyburide [47] and the addition of linagliptin (5mg) to a SU [48]. In addition, 
saxagliptin (2.5 or 5 mg) added to submaximum glyburide (5 or 7.5 mg) therapy led to statistically significant 
improvements vs upti-tration of glyburide alone (up to 15 mg) across key glycaemic parameters, with no 
significant differences in the reported incidences of hypoglycaemic events after a follow-up of 24 weeks [49] and 
76 weeks [50]. However, while the association of gliptin-metformin did not lead to hypoglycaemia, 
hypoglycaemic events may arise with the combination of gliptin-SU. This means that, in T2DM patients with 
moderately increased HbA1c levels taking SU as monotherapy, it may be safer to reduce the SU dose when a 
DPP-4 inhibitor is added to minimize the risk of hypoglycaemia, especially in elderly patients. 
 
Table 1 : Head-to-head trials comparing a DPP-4 inhibitor and an active glucose-lowering agent (metformin, a 
thiazolidinedione or acarbose) in drug-naive type 2 diabetes mellitus (T2DM) patients. 










Sitagliptin Goldstein et al., 2007 [13] 
 
1091 24 Sitagliptin 100 -0.66 20 0 
    Metformin 1000 -0.82 23 -0.6 
    Metformin 2000 -1.13 38 -1.3 
 Williams-Herman et al., 2009 [14] 885 54 Sitagliptin 100 -0.80 23 +0.6 
    Metformin 1000 -1.00 25 -1.0 
    Metformin 2000 -1.30 44 -1.5 
 Williams-Herman et al., 2010 [15] 454 104 Sitagliptin 100 -1.20 32 +0.5 
    Metformin 1000 -1.10 28 -0.8 
    Metformin 2000 -1.30 45 -2.4 
 Aschner et al., 2010 [16] 1050 24 Sitagliptin 100 -0.43 69 -0.6 
    Metformin 2000 -0.57 76 -1.9 
Vildagliptin Schweizer et al., 2007 [12] 780 52 Vildagliptin 100 -1.0 35 +0.3 
    Metformin 2000 -1.4 45 -1.9 
 Göke et al., 2008 [17] 305 104 Vildagliptin 100 -1.0 NA +0.5 
    Metformin 2000 -1.5 NA -2.5 
 Schweizer et al., 2009 [18] 335 24 Vildagliptin 100 -0.64 49 -0.45 
    Metformin 1500 -0.75 61 -1.25 
 Bosi et al.,2009 [19] 589 24 Vildagliptin 100 -1.1 40 -0.59 
    Metformin 2000 -1.4 44 -1.62 
 Rosenstock et al., 2007 [24] 786 24 Vildagliptin 50 -1.1 NA -0.3 
    Rosiglitazone 8 -1.3 NA + 1.6 
 Rosenstock et al., 2007 [22] 607 24 Vildagliptin 100 -1.1 42 +0.2 
    Pioglitazone 30 -1.4 43 + 1.5 
 Pan et al., 2008 [25] 661 24 Vildagliptin 100 -1.4 46 -0.4 
    Acarbose (up to 300) -1.3 47 -1.7 
Saxagliptin Jadzinsky et al., 2009 [20] 663 24 Saxagliptin 10 -1.7 32 -1.1 
    Metformin 500-2000 -2.0 41 -1.6 
 Pfützner et al., 2011 [21] 428 76 Saxagliptin 10 -1.55 25 -0.3 
    Metformin 500-2000 -1.79 35 -1.0 
Alogliptin Rosenstock et al., 2010 [23] 327 26 Alogliptin 25 -0.96 24 -0.3 
    Pioglitazone 30 -1.15 34 +2.2 
Linagliptin Kawamori et al., 2010 [26] 481 26 Linagliptin 5 -0.44 30 NA 
    Linagliptin 10 -0.48 34 NA 
    Voglibose 0.6 -0.10 22 NA 
∆: change vs baseline; BW: body weight; NA: not available. a 53 mmol/mol. 
 
3.2.2. Gliptins combined with thiazolidinediones 
Given the pathophysiology of T2DM, the combination of an insulin secretagogue, such as a DPP-4 inhibitor, and 
an insulin sensitizer, such as TZD, may appear to be an appealing approach [51]. In fact, each of the five studied 
DPP-4 inhibitors was able to further reduce HbA1c levels by almost 1% and increase the proportion of patients 
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with HbA1c levels < 7% (53 mmol/mol) by 15-20% when added to pioglitazone, without increasing 
hypoglycaemic episodes and with minimal weight increases (Table 3). All these studies compared the effect of 
adding a DPP-4 inhibitor vs a placebo [52-58]. 
Only one study used an active comparator instead of a placebo to evaluate the DPP-4 inhibitor added to TZD. In 
this controlled trial, the effects of the addition of sitagliptin (100 mg once a day) or metformin (850 mg twice a 
day) to pioglitazone monotherapy in poorly controlled T2DM patients showed improvements in HbA1c, fasting 
plasma glucose and postprandial glucose levels with both interventions. However, metformin also led to a 
decrease in body weight, and to faster and better improvements in insulin resistance and inflammatory state 
parameters, even though sitagliptin led to better protection of β-cell function. However, an important limitation 
of the study was that the dose of piogliazone was different between the two arms (15 mg with metformin and 30 
mg with sitagliptin; Table 3) [59]. In another study from the same group, a pioglitazone plus vildagliptin 
combination was more effective in preserving β-cell function, and reducing insulin resistance and inflammatory 
state parameters, despite similar improvements in glucose control parameters compared with the glimepiride plus 
vildagliptin combination [60]. 
Thus, the combination of a DPP-4 inhibitor with piogli-tazone may be an effective and safe therapeutic approach 
in patients with T2DM who cannot tolerate either metformin or SU [61]. 
 
Fig. 1. Mean changes (95% confidence interval) in HbA1c (upper) and body weight (lower) in head-to-head 
trials comparing a gliptin and metformin in drug-naive patients (10 trials), a gliptin and a sulphonylurea (SU) in 
metformin-treated patients (eight trials), and a gliptin and a glitazone (TZD) in both drug-naive and metformin-
treated patients (eight trials). P values are for between-treatment differences. Note that some trials were 
computed twice or three times, as specific reports were published after various follow-up durations (24, 54 
and/or 104 weeks). 
 
 
Table 2 : Head-to-head trials comparing a DPP-4 inhibitor and an active glucose-lowering agent 
(sulphonylurea, thiazolidinedione, exenatide or liraglutide), and one trial of sitagliptin vs saxagliptin, in type 2 
diabetes mellitus (T2DM) patients already treated with metformin (> 1500 mg/day). 










Sitagliptin Nauck et al., 2007 [27] 1172 52 Sitagliptin 100 -0.67 63 -1.5 
    Glipizide 5-20 -0.67 59 +1.1 
 Seek et al., 2010 [28] 1172 104 Sitagliptin 100 -0.54 63 -1.6 
    Glipizide 5-20 -0.51 59 +0.7 
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 Arechavaleta et al., 2011 [29] 1035 30 Sitagliptin 100 -0.47 52 -0.8 
    Glimepiride 1-6 -0.54 60 +1.2 
 Scott et al., 2008 [35] 273 18 Sitagliptin 100 -0.73 55 -0.4 
    Rosiglitazone 8 -0.79 63 +1.5 
 Bergenstal et al., 2010 [36] 514 26 Sitagliptin 100 -0.9 30 -0.8 
    Pioglitazone 45 -1.2 43 +2.8 
    Exenatide 2  
once weekly sc 
-1.5 59 -2.3 
 Pratley et al., 2010 [40] 665 26 Sitagliptin 100 -0.9 21 -0.96 
    Liraglutide 1.2 -1.24 44 -2.86 
    Liraglutide 1.8 -1.50 55 -3.38 
 Pratley et al., 2011 [41] 497 52 Sitagliptin 100 -0.88 27 -1.16 
    Liraglutide 1.2 -1.29 50 -2.78 
    Liraglutide 1.8 -1.51 63 -3.68 
Vildagliptin Ferrannini et al., 2009 [30] 2789 52 Vildagliptin 100 -0.44 54 -0.2 
    Glimepiride 1-6 -0.53 56 +1.6 
 Matthews et al., 2010 [31] 3118 104 Vildagliptin 100 -0.1 37 -0.3 
    Glimepiride 1-6 -0.1 38 +1.2 
 Filozof et al.,2010 [32] 1007 52 Vildagliptin 100 -0.81 30 +0.08 
    Gliclazide 80-320 -0.85 32 +1.36 
 Bolli et al., 2008 [37] 576 24 Vildagliptin 100 -0.9 27 +0.3 
    Pioglitazone 30 -1.0 36 +1.9 
 Bolli et al., 2009 [38] 576 52 Vildagliptin 100 -0.6 NA +0.2 
    Pioglitazone 30 -0.6 NA +2.6 
 Blonde et al., 2009 [39] 2478 12 Vildagliptin 100 -0.68 60 -0.6 
    TZD (variable) -0.57 52 +0.3 
Saxagliptin Göke et al., 2010 [33] 858 52 Saxagliptin 5 -0.74 43 -1.1 
    Glipizide 5-20 -0.80 48 +1.1 
Alogliptin No published trial       
Linagliptin Forst et al., 2010 [34] 333 12 Linagliptin 1 -0.40 15 -0.15 
    Linagliptin 5 -0.73 15 -0.57 
    Linagliptin 10 -0.67 21 -1.27 
    Glimepiride 1-3 -0.90 NA +0.73 
Saxa- vs Scheen et al.,2010[42] 801 18 Sitagliptin 100 -0.62 39 -0.4 
Sitagliptin    Saxagliptin 5 -0.52 33 -0.4 
∆: change vs baseline; BW: body weight; se: subcutaneous; NA: not available; TZD: thiazolidinedione (pioglitazone or rosiglitazone). a 53 
mmol/mol. 
 
Table 3 : Head-to-head trials comparing a DPP-4 inhibitor and a placebo or an active glucose-lowering agent 
(uptitration of initial dose of sulphonylurea [SU] or metformin) in type 2 diabetes mellitus (T2DM) patients 
already treated with a SU or a thiazolidinedione (TZD). 












Add-on to SU         
Sitagliptin Hermansen et al., 2007 [45] 212 24 Glimepiride Sita 100 -0.30 11 + 1.1
    >4 Placebo +0.27 9 0 
Vildagliptin Garber et al.,2008 [46] 515 24 Glimepiride 4 Vilda 50  











Saxagliptin Chacra et al.,2009 [49] 768 24 Glyburide 7.5 Saxa 2.5 
Saxa 5 










 Chacra et al.,2011 [50] 557 76 Glyburide 7.5 Saxa 2.5 
Saxa 5 
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Add-on to TZD 








 Derosa et al., 2010 [59] 151 52 Pioglitazone 30 Sita 100 -1.4 NA -1.6 
    Pioglitazone 15 Metformin 1700 -1.4 NA -2.8 
Vildagliptin Garber et al.,2007[53] 463 24 Pioglitazone 45 Vilda 50 



































































∆: change vs baseline; BW: body weight; NA: not available. a 53 mmol/mol. 
b pioglitazone 30-45 mg or rosiglitazone 4-8 mg. c TZD as initial treatment. 
 
 
3.2.3. Gliptins as oral triple therapy 
The arrival of DPP-4 inhibitors offered a new alternative for oral triple therapy (Table 4) at a time when only the 
combination of metformin plus SU plus TZD was available [62]. Again, most studies, except one [63], were 
randomized clinical trials comparing the addition of a gliptin vs a placebo on top of a dual combination of either 
metformin-SU [45,64] or metformin-TZD [65]. Sitagliptin 100mg once daily significantly improved glycaemic 
control and β-cell function in patients with T2DM who had inadequate glycaemic control with glimepiride plus 
metformin therapy [45]. Similarly, adding linagliptin 5 mg to metformin in combination with SU significantly 
improved glycaemic control in T2DM patients and was well tolerated [64]. Adding alogliptin 25 mg to a 
metformin-pioglitazone regimen provided superior glycaemic control and potentially improved β-cell function vs 
uptitrating pioglitazone in T2DM patients, with no clinically important differences in safety [65]. One study 
compared two modalities of triple therapy. Among ethnic-minority T2DM patients poorly controlled with the 
maximum tolerated doses of metformin and SU, third-line add-on therapy with TZD (rosiglitazone 8mg or 
pioglitazone 45 mg) was found to control hyperglycaemia more effectively than sitagliptin 100 mg after 4 
months [63]. 
 
Table 4 : Head-to-head trials comparing a DPP-4 inhibitor and an active glucose-lowering agent in type 2 
diabetes mellitus (T2DM) patients already treated with a combined oral therapy [sulphonylurea (SU) + 
metformin or SU + thiazolidinedione (TZD)] or insulin (with or without metformin). 















23 1 +0.4 
-0.7 








Vildagliptin No published trial        
Saxagliptin No published trial        




33 21 + 1.1 
+ 1.6
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29 8 +0.27 
-0.06
Add-on to insulin 
Sitagliptin Visboll et al., 2010 [67] 641 24 Insulin Sita 100 
Placebo 












Saxagliptin Barnett et al., 2011 [69] 455 52 Insulin Saxa 5 -0.80 21 +0.8 
    30-150 units Placebo -0.40 9 +0.5 












Linagliptin No published trial        
∆: change vs baseline; BW: body weight; NA: not available. a 53 mmol/mol. b < 7.5% (58 mmol/mol) instead of < 7% (53 mmol/mol). 
 
3.2.4. Gliptins combined with insulin in type 2 diabetes mellitus 
Insulin therapy in T2DM patients is frequently initiated while oral glucose-lowering agents (most often 
metformin, sometimes SU) are maintained, at least in part. Therefore, it may also be possible to speculate on the 
clinical efficacy of combining a DPP-4 inhibitor with insulin. Four placebo-controlled trials have investigated 
the clinical efficacy and safety of adding a DPP-4 inhibitor to a basal insulin regimen (with or without metformin 
or SU; Table 4) [66-69]. All studies reported consistent results, with a reduction in HbA1c levels of 0.5-0.6% on 
average if daily insulin dosages were maintained unchanged. These favourable results were obtained with no 
weight gains or increases in the incidence of hypoglycaemia. A reduction in severe hypoglycaemic episodes was 
reported in one trial of insulin plus vildagliptin in T2DM patients poorly controlled with high doses of insulin, 
presumably because of an individual reduction in daily insulin dosage (which resulted in a smaller HbA1c 
reduction of only 0.3%) [66]. In the TRANSITION randomized controlled trial [70], significantly greater 
reductions in HbA1c (-1.44% vs -0.89%; P<0.001) and plasma glucose levels were achieved with the 
combination of insulin detemir + sitagliptin + metformin compared with sitagliptin + metformin ± SU, with no 
increases in the rate of hypoglycaemia. 
Thus, adding a DPP-4 inhibitor to insulin therapy may be useful in T2DM patients for improving glucose control 
without increasing hypoglycaemia, and possibly for limiting weight gain. Further studies are warranted to 
explore the role of a DPP-4 inhibitor added to optimized insulin regimens (premixed insulin preparations or a 
basal-bolus insulin scheme), as the available studies only involved patients using basal insulin therapy. 
3.3.   Gliptins as the initial combination 
Because of the complexity of the pathophysiology of T2DM and the frequently observed primary or secondary 
failure of monotherapy, initial combination treatment may be considered to offer more efficacious management 
of T2DM [51]. Several clinical trials have evaluated initial combinations of either metformin + gliptin [13-15,19-
21,71] or TZD + gliptin [22,23,58,72] and compared the results with an initial monotherapy (Table 1). However, 
none of these trials evaluated an initial combination including a DPP-4 inhibitor vs another initial combination 
not including a gliptin in a head-to-head comparison. 
The initial combination of sitagliptin (2 × 50 mg) or vildagliptin (2 × 50 mg) with metformin (low dose of 2 × 
500 mg or high dose of 2 × 1000 mg) had superior efficacy compared with monotherapy treatments, with 
comparable overall tolerability profiles and low risk of hypoglycaemia [13-15,19-21,71]. Similar results were 
obtained with the initial combination of saxagliptin 5 or 10 mg plus metformin 500 mg uptitrated to 2000 mg 
[20,21]. These favourable results were observed in both short-term (18-24 weeks) and long-term (54-104 weeks) 
clinical trials. The potential dose-sparing effect of adding a DPP-4 inhibitor to relatively low-dose metformin in 
preference to metformin uptitration may allow patients to achieve equivalent or superior HbA1c-lowering without 
the gastrointestinal tolerability issues associated with higher doses of metformin [73]. 
Similar results have been reported with the initial combination of TZD-gliptin [22,23,58,72]. Reductions in 
HbA1c of 1-2.4% vs baseline have been reported and were always significantly greater than those observed with 
monotherapy with either TZD or a DPP-4 inhibitor. In addition, first-line combined treatments had minimal risks 
of hypoglycaemia, led to similar or only slightly more weight gain than pioglitazone on its own and offered a 
tolerability profile comparable to component monotherapy. Thus, such combinations may offer a valuable 
adjunctive initial treatment option for T2DM, particularly in cases where metformin is contraindicated, as in 
patients with renal impairment. 
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3.4.  Head-to-head trials comparing incretin-based therapies 
3.4.1. DPP-4 inhibitors vs GLP-1 receptor agonists 
Incretin-based agents include GLP-1 receptor agonists, which mimic endogenous GLP-1, and DPP-4 inhibitors, 
which inhibit the breakdown of endogenous incretin hormones [74,75]. This means that both GLP-1 receptor 
agonists and DPP-4 inhibitors elevate GLP-1 activity and substantially improve glycaemic control. Indirect 
comparisons reported in meta-analyses of randomized controlled trials have shown that GLP-1 receptor agonists 
are more effective in lowering blood glucose and result in substantial weight loss, whereas therapy with DPP-4 
inhibitors lowers blood glucose levels to a lesser degree and is weight-neutral [8]. However, head-to-head 
comparisons of the two therapies are scarce, and only one DPP-4 (sitagliptin) has been so evaluated. Two trials 
compared sitagliptin 100 mg vs exenatide either twice daily [76] or once weekly [36], and a further trial 
compared sitagliptin 100 mg with liraglutide once daily [40] (Table 2). 
In a trial comparing short-term (2-week) treatment with exenatide (5 µg twice daily for 1 week, then 10 µg twice 
daily for 1 week) vs sitagliptin 100 mg once daily, the results were better with exenatide treatment, as assessed in 
terms of lowering postprandial glucose, increasing insulin levels, decreasing glucagon levels and decreasing 
caloric intakes [76]. A 26-week, randomized, double-dummy superiority trial assessed the safety and efficacy of 
exenatide 2mg once a week vs sitagliptin 100 mg once a day in patients treated with metformin. Treatment with 
exenatide reduced HbA1c significantly more than did sitagliptin, with greater weight loss and no episodes of 
major hypoglycaemia (Table 2). However, exenatide was associated with more nausea and diarrhoea than 
sitagliptin [36]. Also, an extension of the study showed that patients who switched to once-weekly exenatide 
from daily sitagliptin had improved or sustained glycaemic control (HbA1c-0.3%) and weight loss (-1.1 %) [77]. 
In a 24-week prospective trial comparing treatment with liraglutide (1.2 or 1.8 mg once daily) vs sitagliptin 100 
mg in metformin-treated patients with T2DM, reductions in HbA1c and body weight were significantly greater 
with both dosages of liraglutide than with sitagliptin, but at the cost of an increased incidence of minor side-
effects such as nausea and vomiting (Table 2) [40]. Incidences of hypoglycaemic events were low (5%) and 
similar in all treatment groups. These data were also confirmed after 1 year [41]. 
Although GLP-1 receptor agonists demonstrate superiority compared with DPP-4 inhibitors, the average modest 
differences in HbA1c and weight reductions may be counterbalanced by several disadvantages of GLP-1 receptor 
agonists (injected vs oral, more nausea, more expensive). Other possible additional advantages remain to be 
demonstrated, such as better cardiovascular protection and longer duration of glucose control [5,74,75]. 
3.4.2. Head-to-head comparisons among gliptins 
As DPP-4 inhibitors have heterogeneous chemical structures and various pharmacokinetic characteristics, this 
raises the question of possible between-gliptin differences in efficacy and safety profiles [78]. The different 
DPP-4 inhibitors are distinctive in their metabolism (saxagliptin and vildagliptin are metabolized in the liver 
whereas sitagliptin is not), excretion (linagliptin is excreted mostly unchanged by the liver, unlike other DPP-4 
inhibitors, which are mainly eliminated via the kidneys) and potential for cytochrome-mediated drug-drug 
interactions (observed with saxagliptin, but not with other gliptins). Certain of these differences may be 
clinically relevant, especially in patients with renal impairment (see below). Nevertheless, all DPP-4 inhibitors 
are similar when comparing their mode of action (as 'incretin enhancers'), efficacy in lowering HbA1c levels, 
safety profile (no risk of severe hypoglycaemia) and patient tolerability. Also, as there were no significant 
differences seen with exposure to any tested DPP-4 inhibitor in patients with mild, moderate or even severe 
hepatic impairment, it appears that no dose adjustment is necessary in patients with liver disease, not even for 
linagliptin despite its specific biliary excretion [5,78,79]. 
In the absence of head-to-head comparative randomized trials of different DPP-4 inhibitors (for instance, 
sitagliptin vs vildagliptin), any information can only be found through indirect comparisons. In a meta-analysis 
of 12 trials with sitagliptin and 11 trials with vildagliptin, the weighted mean differences vs placebo were -0.79% 
(95% CI: -0.93 to -0.65) for sitagliptin and -0.67% (95% CI: -0.83 to -0.52) for vildagliptin [8]. In a matching-
adjusted indirect comparison of trials in Japanese patients with T2DM, vildagliptin 50 mg twice daily was 
associated with a slightly but significantly greater HbA1c reduction than sitagliptin 50 mg (difference: 0.28%) or 
100 mg (difference: 0.35%) once daily [80]. 
However, head-to-head comparisons are scarce, and only one trial has been published as a full report so far. In 
this 18-week non-inferiority trial comparing the efficacy of saxagliptin 5mg once daily and sitagliptin 100 mg 
once daily in T2DM patients with glycaemia inadequately controlled by metformin, the adjusted mean changes 
in HbA1c were - 0.52% and -0.62%, respectively (Table 2). The between-group difference was 0.09% (95% CI: -
0.01 to 0.20%), demonstrating non-inferiority. The safety profile was similar for the two DPP-4 inhibitors, with 
modest weight loss and almost no increase in the incidence of reported or documented hypoglycaemic episodes 
[42]. 
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3.5. Gliptins in special populations 
3.5.1. Patients with renal impairment 
Therapeutic options for patients with T2DM and chronic kidney disease are limited because a reduced 
glomerular filtration rate (GFR) results in the accumulation of certain drugs and/or their metabolites [81]. The 
pharmacokinetic characteristics of five DPP-4 inhibitors have been studied in subjects with varying degrees of 
renal impairment (RI): mild = creatinine clearance 50-80 mL/min; moderate = 30-50 mL/min; and severe = < 30 
mL/min, including patients with end-stage renal disease (ESRD) [5,82]. According to the results, dose 
adjustment according to creatinine clearance is recommended for sitagliptin (50 mg in cases of moderate RI and 
25 mg in cases of severe RI), saxagliptin (2.5 mg instead of 5 mg in cases of moderate or severe RI) and 
vildagliptin (50 mg once a day instead of 50 mg twice a day). However, no dose adjustments are recommended 
for linagliptin. 
Several post-hoc analyses of phase-III or specific clinical trials have also evaluated both the efficacy and safety 
of DPP-4 inhibitors in T2DM patients with various degrees of RI. With dose adjustment in a 54-week trial, 
sitagliptin was generally well tolerated and provided effective glycaemic control in patients with T2DM and 
moderate-to-severe RI, including patients with ESRD on dialysis [83]. However, in a study assessing dose 
adjustments of glucose-lowering agents in T2DM patients with moderate to end-stage RI from a large outpatients 
electronic medical records database, only 15% of patients with prescriptions for sitagliptin received dosages of 
the drug appropriate for their degree of RI. Thus, in clinical practice, sitagliptin was frequently used at 
inappropriate dosages in patients with RI [84]. 
Saxagliptin 2.5 mg once daily proved to be a well-tolerated treatment option for patients with inadequately 
controlled T2DM and various degrees of RI, with incidences of adverse events and hypoglycaemic events similar 
to those with a placebo [85]. In a 12-week study, the reduction in HbA1c was greater with saxagliptin than with a 
placebo in subgroups of patients with moderate and severe RI, but not in the subgroup with ESRD on 
haemodialysis. These observations were recently confirmed in a longer follow-up of 52 weeks [86]. 
A retrospective analysis demonstrated similar safety and tolerability of vildagliptin as an add-on to metformin in 
T2DM patients with normal renal function and mild RI [87]. Data pooled from 38 studies in which vildagliptin 
was given for 12 to 104 weeks in patients with T2DM showed that it was effective and well tolerated in the 
presence of mild or moderate RI [88]. In a recent 24-week study of 515 T2DM patients with moderate or severe 
RI, vildagliptin added to ongoing antidiabetic therapy had a safety profile similar to that with a placebo. 
Furthermore, compared with a placebo, vildagliptin resulted in a statistically and clinically significant decrease 
in HbA1c in patients with moderate or severe RI [89]. 
In a large phase-III 24-week study comparing linagliptin 5 mg once daily with a placebo in patients with T2DM, 
having mild or moderate RI did not influence trough plasma levels of linagliptin [90]. Also, the efficacy 
(reduction of HbA1c levels) and safety of linagliptin 5 mg was confirmed in T2DM patients with mild or 
moderate RI in a pooled analysis of three randomized, placebo-controlled, phase-III clinical trials, as well as in 
T2DM patients with severe RI (GFR<30mL/min/1.73m2) in a randomized, double-blind, placebo-controlled trial 
specifically targeting such a population [79]. 
3.5.2. Elderly patients 
Oral DPP-4 inhibitors are promising new therapies for older patients because of their consistent efficacy and low 
risk of hypo-glycaemia. However, data for these new agents are still scarce in this population, which has not 
been particularly well represented in initial clinical trials, highlighting the need for additional specific studies [5]. 
However, where available, data from elderly subgroups in individual studies are included in this present review 
along with pooled analyses by age subgroups in clinical programmes involving DPP-4 inhibitors [91]. For 
elderly patients with T2DM, reductions in HbA1c after treatment with a DPP-4 inhibitor were not significantly 
different from those seen in younger patients. This was demonstrated in post-hoc pooled analyses of 24-week 
trials with vildagliptin 100 mg monother-apy in treatment-naive patients aged > 65 years vs those < 65 years 
[92], and with vildagliptin 100 mg as monotherapy or as add-on therapy to metformin in patients aged > 75 years 
vs those < 75 years [93]. The safety profile of vildagliptin was similar in older and younger patients overall. Use 
of DPP-4 inhibitors in these studies was associated with a low risk of hypoglycaemia, and the agents were 
weight-neutral [94]. 
Similar observations have been reported with saxagliptin 5 mg once-daily as monotherapy or as add-on therapy 
[95], and with alogliptin [47] in T2DM patients aged > 65 years. 
So far, only one clinical trial has been specifically performed in elderly T2DM patients. In this placebo-
controlled, 24-week study, sitagliptin treatment (100 or 50 mg, depending on renal function) significantly and 
rapidly improved glycaemic measures (reductions in HbA1c from 0.5% to 1.6%, depending on baseline levels), 
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and was well tolerated with no adverse episodes of hypoglycaemia in patients aged > 65 years with T2DM 
without severe RI [96]. 
Although, so far, there are no available studies of elderly individuals with linagliptin, a specific trial is currently 
ongoing. However, because of the unique pharmacokinetic characteristics of the compound (in particular, its 
non-renal elimination route), it is unlikely that any clinically relevant efficacy/safety differences in older vs 
younger patients with T2DM will be seen with linagliptin therapy [79]. 
 
4.  Pharmacoeconomic evaluation 
Although newer incretin-based therapies offer more options for glycaemic control in T2DM and certain 
advantages compared with other classical glucose-lowering agents [3,4], the cost of the therapy needs to be taken 
into account when making global comparisons for clinical use [97]. DPP-4 inhibitors are clearly more expensive 
than SUs, but less expensive than GLP-1 receptor agonists [98]. This means that demonstrable gains in quality of 
life and/or longevity with these new agents are necessary to prove their economic value to both patients and 
healthcare systems [99]. Although there are favourable cost-effectiveness and cost-utility data for DPP-4 
inhibitors compared with SUs, only scanty preliminary data are currently available [100]. Thus, more economic 
analyses are required to establish when it will become more cost-effective to switch from SUs to DPP-4 
inhibitors [97]. 
 
5.  Conclusion 
Despite the wide structural heterogeneity among gliptins and differences in their pharmacokinetic profiles, the 
data available so far indicate similar glucose-lowering efficacy with DPP-4 inhibitors as either monotherapy or 
in combination with other hypoglycaemic drugs, similar weight-neutral effects, and comparable safety and 
tolerability profiles. A composite endpoint including HbA1c reduction, no hypoglycaemia and no weight gain 
could be used to combine both efficacy and safety criteria, and so provide an integrated benefit/risk ratio for 
clinical use. Significantly more patients treated by a DPP-4 inhibitor achieved an HbA1c level < 7% 
(53mmol/mol) or an HbA1c reduction > 0.5%, with no hypoglycaemia and no increase in body weight compared 
with a SU, and with no weight gain compared with a TZD. This advantage was confirmed with monotherapy in 
drug-naive T2DM patients as well as with combination therapy mainly with metformin, and the potential 
advantages of initiating combined metformin-gliptin therapy have been demonstrated in several trials. DPP-4 
inhibitors also showed good efficacy as dual therapy in combination with SU or TZD and as oral triple therapy, 
and when added to basal insulin treatment in T2DM patients. Thus, combination therapy with a DPP-4 inhibitor 
offers the potential advantage of achieving glycaemic control with no additional tolerability concerns. 
Prospective long-term clinical trials are ongoing to confirm the safety/efficacy of DPP-4 inhibitors added to any 
type of glucose-lowering therapies as regards cardiovascular outcomes [5]. However, it is noteworthy that most 
of these studies are placebo-controlled trials, and none will directly compare two incretin-based therapies. 
Nevertheless, as these trials plan to recruit more than 50,000 T2DM patients and to follow them for 4-5 years, 
they should provide further valuable information on the long-term efficacy/safety of this new incretin-based class 
of pharmacological agents. 
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